Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China.
School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore, 639798, Singapore.
Adv Healthc Mater. 2019 Apr;8(8):e1801318. doi: 10.1002/adhm.201801318. Epub 2019 Mar 4.
Therapeutic strategy based on the restoration of tumor suppressor-microRNAs (miRNAs) is a promising approach for cancer therapy, but the low delivery efficiency of miRNA remains a huge hurdle due to the lack of safe and efficient nonviral carriers. In this work, with the use of newly developed PEGylated biodegradable charged polyester-based vectors (PEG-BCPVs) as the carrier, the miR26a and miR122 codelivering therapeutic strategy (PEG-BCPVs/miR26a/miR122 as the delivery formulation) is successfully developed for efficient treatment of human hepatocellular carcinoma (HCC). In vitro study results show that PEG-BCPVs are capable of effectively facilitating miRNA cellular uptake via a cell endocytosis pathway. Consequently, the restoration of miR26a and miR122 remarkably inhibit the cell growth, migration, invasion, colony formation, and induced apoptosis of HepG2 cells. More importantly, the chemosensitivity of HepG2 to anticancer drug is also considerably enhanced. After treatment with the PEG-BCPV-based miRNA delivery system, the expression of the multiple targeted genes corresponding to miR26a and miR122 in HepG2 cells is greatly downregulated. Accordingly, the newly developed miRNA restoration therapeutic strategy via biodegradable PEG-BCPVs as the carrier should be a promising modality for combating HCC.
基于肿瘤抑制因子-微小 RNA(miRNA)恢复的治疗策略是癌症治疗的一种很有前途的方法,但由于缺乏安全有效的非病毒载体,miRNA 的递药效率仍然很低。在这项工作中,我们使用新开发的聚乙二醇化可生物降解带电聚酯载体(PEG-BCPVs)作为载体,成功开发了 miR26a 和 miR122 共递药治疗策略(PEG-BCPVs/miR26a/miR122 作为递药制剂),用于有效治疗人肝癌(HCC)。体外研究结果表明,PEG-BCPVs 能够通过细胞内吞作用途径有效地促进 miRNA 的细胞摄取。因此,miR26a 和 miR122 的恢复显著抑制 HepG2 细胞的生长、迁移、侵袭、集落形成和诱导凋亡。更重要的是,还显著增强了 HepG2 对抗癌药物的化疗敏感性。在用基于 PEG-BCPV 的 miRNA 递药系统治疗后,HepG2 细胞中对应 miR26a 和 miR122 的多个靶向基因的表达大大下调。因此,新开发的基于可生物降解 PEG-BCPVs 的 miRNA 恢复治疗策略作为载体,应该是对抗 HCC 的一种很有前途的方法。